Search
Nesvacumab
go.drugbank.com/drugs/DB15330InvestigationalNesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or
AVXS-301
go.drugbank.com/drugs/DB17943ExperimentalIt is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077]
Lycopene
go.drugbank.com/drugs/DB11231ApprovedLycopene is a non-essential human nutrient that is classified as a non-provitamin A carotenoid pigment since it lacks a terminal beta-ionone ring [A27242] and does not mediate vitamin A activity.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawnIt is not approved for use in the United States.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. … It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.
Tanaproget
go.drugbank.com/drugs/DB04787ExperimentalIt is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins.
PS386113
go.drugbank.com/drugs/DB05211ExperimentalIt is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
BBM-H901
go.drugbank.com/drugs/DB17704InvestigationalIt is being investigated for the treatment of hemophilia B.[A259048]
FB-101
go.drugbank.com/drugs/DB17956InvestigationalDeveloped by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]
Tulrampator
go.drugbank.com/drugs/DB16344InvestigationalTulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive